IBRANCE® IS THE FIRST FDA-APPROVED MEDICATION in its class. IBRANCE is a targeted therapy known as a CDK 4/6 inhibitor. It is not a traditional chemotherapy. Taken in combination with certain hormonal therapies, IBRANCE works to put the brakes on cell growth in both healthy and cancer cells. This helps slow the progression of cancer, but it can also cause side effects, some of which are serious. Please see Important Safety Information.
In combination with any aromatase inhibitor, IBRANCE is for postmenopausal women as their first hormonal based therapy.
IBRANCE was studied in a clinical trial of 666 postmenopausal women with ER+/HER2- metastatic breast cancer who had not received prior hormone therapy for their metastatic disease. Patients were split into 2 groups. The first group took IBRANCE and letrozole (an aromatase inhibitor) together, while the second group took letrozole and placebo.
DELAYED DISEASE PROGRESSION
MEDIAN TIME TO DISEASE PROGRESSION
Together, the combination of IBRANCE and letrozole delayed disease progression for a median time of 24.8 months versus 14.5 months for those that received letrozole and placebo. Patients taking IBRANCE with letrozole reduced their risk of disease progression by 42% compared to those taking letrozole and placebo.
This means that IBRANCE plus letrozole was significantly more effective at delaying disease progression versus letrozole and placebo.
In the same clinical trial, tumor response to treatment was measured. The results showed that in patients taking IBRANCE and letrozole, tumor response was 55%—meaning more than half of these patients saw their tumors shrink in size —compared to 44% who took letrozole and placebo.
TALKING TO YOUR DOCTOR
Find helpful questions to ask your doctor about IBRANCE.
How IBRANCE Works
SLOWING THE PROGRESSION OF METASTATIC BREAST CANCER
IBRANCE is a targeted therapy known as a CDK 4/6 inhibitor. It is not a traditional chemotherapy. IBRANCE works to put the brakes on cell growth in both healthy and cancer cells. This helps slow the progression of cancer, but it can also cause side effects, some of which are serious. Please see theto learn more.
Learn How IBRANCE & Hormonal Therapies Work Together
IBRANCE and hormonal therapies bring the power of two therapies together to help delay the progression of a certain type of metastatic breast cancer.
Use the green arrows to navigate the animation below, demonstrating how IBRANCE works to inhibit CDK 4/6 and how hormonal therapies play a role in reducing the effects of hormones in the body.
While on therapy, be sure to share any side effects you experience with your healthcare team right away.
SERIOUS SIDE EFFECTS
- Low white blood cell counts (neutropenia) are very common when taking IBRANCE (palbociclib) and may cause serious infections that can lead to death. Your healthcare team should check your white blood cell counts before and during treatment.
- If you develop low white blood cell counts during treatment with IBRANCE, your doctor may stop your treatment, decrease your dose, or may tell you to wait to begin your treatment cycle. Tell your doctor right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills.
COMMON SIDE EFFECTS
- In addition to low white blood cell counts (neutropenia), low red blood cell counts and low platelet counts are common with IBRANCE. Call your healthcare team right away if you feel dizzy or weak, notice that you bleed or bruise more easily, or experience shortness of breath or nosebleeds while on treatment.
- Other common side effects include infections, tiredness, nausea, sore mouth, abnormalities in liver blood tests, diarrhea, hair thinning or hair loss, vomiting, rash, and loss of appetite.
Not all of the possible side effects are listed here. For more information, talk to your doctor, nurse, or pharmacist.
Brochures To Download
Download our Patient Brochure for an overview of IBRANCE.
Download our Caregiver Guide for information specific for caregivers.